In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)
Metabolic Profiling of Leukemic Cells Through Isotope Tracing in Patients With CLL
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 18 Years and older
- Sex
- All sexes
- Healthy volunteers
- Accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
Not stated in the study description — ask the study team about visits and procedures.
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
In plain language
This study looks at how cells in chronic lymphocytic leukemia (CLL), a type of blood cancer, use nutrients for fuel. It uses nutrients with non-radioactive labels to track how cells use them. It is for adults with untreated CLL and adults who have never had cancer.
Metabolic reprogramming has been identified as a hallmark of cancer. Almost a century after Otto Warburg initially discovered increased glycolytic activity in tumor tissue ("Warburg effect"), therapeutic targeting of cancer metabolism has become a field of intense research effort in cancer biology. A growing appreciation of metabolic heterogeneity and complexity is currently reshaping investigators "simplistic" understanding of metabolic reprogramming in cancer. Discovering metabolic vulnerabilities as new treatment targets for cancer requires systematic dissection of metabolic dependencies, fuel preferences, and underlying mechanisms in the specific physiological context. However, today's data on cancer cell metabolic signatures and heterogeneity in their physiological habitat of the human organism is sparse to non-existent representing a critical knowledge gap in designing effective metabolic therapies. Here, the investigators propose a "top-down" approach studying cancer cell metabolism in patients followed by mechanistic in-depth studies in cell culture and animal models to define metabolic vulnerabilities. Investigators will develop a metabolic tracing method to quantitatively characterize metabolic signatures and fuel preferences of leukemic lymphocytes in patients with chronic lymphocytic leukemia (CLL). Isotopic metabolic tracers are nutrients that are chemically identical to the native nutrient. Incorporated stable, non-radioactive isotopes allow investigators to follow their metabolic fate by monitoring conversion of tracer nutrients into downstream metabolites using cutting-edge metabolomics analysis. Using this method, investigators propose to test the hypothesis that leukemic lymphocytes show tissue-specific metabolic preferences that differ from non-leukemic lymphocytes and that ex vivo in-plasma labeling represents a useful model for assaying metabolic activity in leukemic cells in a patient-specific manner.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Who can join
- All groups: Age 18 or older and have given documented consent to join.
- Group A: Never had cancer, with a history of normal blood counts and vital signs.
- Group B: Have untreated CLL at Rai stage 0: extra white blood cells, no enlarged lymph nodes, spleen, or liver, and nearly normal red blood cell and platelet counts.
- Group C: Have untreated CLL that has spread into the bone marrow and caused low blood cell counts.
- Group C: Able and willing to have a bone marrow aspiration, which uses a needle to take a sample from inside a bone.
Who can't join
- Are under age 18 or do not meet the entry rules above.
- Are a prisoner, a patient staying in a psychiatric hospital, or living in an institution.
- Have a history of diabetes or take medicine to lower blood sugar.
- Follow a diet listed as restricting carbohydrates, such as Atkins, vegan, or ketogenic.
- Are female and able to become pregnant.
- Cannot make your own decisions.
- Cannot read or write English.
Simplified for readability. The official criteria below are what the study team uses.
Official eligibility criteria
Inclusion Criteria: Group A * Adult (18 years of age or older) * No previous history of cancer * Routine history of normal blood counts and vital signs * Documented Informed Consent Group B * Adult (18 years of age or older) * Diagnosis of CLL with low disease burden defined as Rai stage 0 ((Lymphocytosis; no enlargement of the lymph nodes, spleen, or liver; red blood cell and platelet counts are near normal.) * Treatment naïve * Documented Informed Consent Group C * Adult (18 years of age or older) * Diagnosis of CLL with high systemic disease burden defined as infiltration of bone marrow causing cytopenia * Treatment naïve * Able/willing to have bone marrow aspiration * Documented Informed Consent Exclusion Criteria: For all participants * Prisoners * Psychiatric inpatients or people who are institutionalized * Minor (Less than 18 years of age) * History of diabetes * Cannot be on antihyperglycemic therapy * Carbohydrate restricting diets: Atkins, Vegan, Ketogenic, etc. * Females of child bearing potential * Persons without decision-making capacity * Person who cannot read/write English * Not meeting inclusion criteria defined above
Study sites (1)
WI
- University of Wisconsin · Madison, WI 53705More trials in Madison